Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
When Security Creates Scarcity: DSCSA’s Unintended Consequence
June 2, 2025
In a recent article, A&M Life Sciences experts discuss The Drug Supply Chain Security Act and how well-intentioned regulations may be straining the very system they’re meant to safeguard.
Medtech CDMOs in 2025: Perspectives on Activity in the Medtech CDMO Market
May 19, 2025
Driving the future of medical innovation, Medtech CDMOs are leveraging strategic M&A and advanced technologies to scale growth. Amid regulatory complexity, key players are accelerating development and meeting rising demand for specialized manufacturing.
